HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9764023
SERIAL NO

14453286

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to novel CD4+ and CD8+ T cell epitopes that are specific for HPV-specific E6 and E7 oncoproteins, to peptides comprising these novel T cell epitopes, and to (vaccine) compositions comprising these peptides for use in methods for the prevention and/or treatment of HPV related diseases. Preferred epitopes are recognized by a T cell that infiltrates a cervical neoplastic lesion or by a T cell from a draining lymph node, and are presented by an HLA-DQ or HLA-DP molecule, or an HLA-B.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • ACADEMISH ZIEKENHUIS LEIDEN H.O.D.N. LUMC

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Kenter, Gemma G Amsterdam, NL 9 46
Melief, Cornelis Johannes Haarlem, NL 2 7
Van, Der Burg Sjoerd Henricus Leiden, NL 13 64

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 19, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 19, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00